PV Bulletin
Health Canada

Health Canada Q&A accepts PSUR or PBRER for C.01.018 reports

Health Canada’s Q&A clarifies that Canada C.01.018 annual summary reports may be prepared in PSUR (ICH E2C(R1)) or PBRER (ICH E2C(R2)) format/content, supporting periodic benefit-risk appraisal and aggregate reporting alignment.

Primary source: Health Canada (Canada.ca)

PV Impact Brief

Urgency: HighConfidence: medium

What changed

Health Canada’s Q&A clarifies that Canada C.01.018 annual summary reports may be prepared in PSUR (ICH E2C(R1)) or PBRER (ICH E2C(R2)) format/content, supporting periodic benefit-risk appraisal and aggregate reporting alignment.

Why it matters

Potential impact spans Local Affiliate Compliance, Inspection Readiness, Risk Management, AI / GxP Governance, Aggregate Reporting, so Local Safety Officer oversight is needed to maintain compliance readiness and evidence traceability.

Action needed

Health Canada update requires triage for Local Affiliate Compliance, Inspection Readiness, Risk Management; confirm local obligations and document follow-up actions.

Relevant for
Local Safety OfficerSignal Management LeadPV Quality LeadPV Technology / CSV LeadAggregate Reports LeadQPPV
Processes impacted
Local Affiliate ComplianceInspection ReadinessRisk ManagementAI / GxP GovernanceAggregate Reporting
Owner

Local Safety Officer

Review cadence

Immediate triage (within 1 business day), then weekly review until closure.

Evidence and confidence

Confidence: mediumSource update date not verified — confirm on the regulator site before acting

Primary-source confirmation recommended before operational implementation.

Full briefing

Practical implication

Health Canada update requires triage for Local Affiliate Compliance, Inspection Readiness, Risk Management; confirm local obligations and document follow-up actions.

Health Canada published a Q&A (03 Sep 2024) clarifying that Market Authorization Holders (MAHs) can fulfill the annual summary report preparation requirement under Food and Drug Regulations C.01.018 using either a Periodic Safety Update Report (PSUR) or a Periodic Benefit-Risk Evaluation Report (PBRER), provided the report’s format and content align to the relevant ICH guidance (E2C(R1) for PSUR; E2C(R2) for PBRER).

For PV and regulatory operations, this is an evergreen compliance clarification with practical impact on how Canada periodic reporting is planned, documented, and defended under inspection readiness expectations. The Q&A frames the purpose of the associated Notice as informing MAHs that Health Canada will accept these ICH-aligned report formats for the C.01.018 annual summary report requirement.

The Q&A also describes what Health Canada expects a PBRER to represent: a periodic, comprehensive, concise and critical analysis of new or emerging risk information and benefits in approved indications, intended to enable appraisal of the product’s overall benefit-risk profile.

Because the Q&A explicitly ties acceptability to the ICH E2C revision associated with the chosen report type, PV teams should confirm the Canada annual summary report approach (PSUR aligned to ICH E2C(R1) vs PBRER aligned to ICH E2C(R2)) and ensure the corresponding controlled template(s) and QC checklist(s) match the selected format/content.

PV Quality, Regulatory Intelligence, and Aggregate Reporting teams may also wish to update controlled documents (SOPs, work instructions, templates, and report calendar notes) to reflect Health Canada’s acceptance statement for Canada compliance positioning, and ensure an inspection-ready justification is available for the chosen format.

The Q&A references a separate “Notice” in describing its purpose, but that Notice content is not included in the provided evidence; any additional operational details (such as transition timing, submission mechanics, or scope nuances) cannot be confirmed from this source extract.

Apply this clarification before the next Canada annual summary report cycle and monitor the Health Canada Q&A page for revisions or linked Notice updates; for upcoming C.01.018 deliverables, confirm the PSUR vs PBRER approach and lock the selected ICH-aligned format into templates, QC checks, and controlled documents for Canada compliance and inspection readiness.

Related updates for your role

publicEuropean Medicines Agency · EU · Updated Jul 15, 2026

Reflection paper on particulars for safety signals for (traditional) herbal medicinal products

Urgency: High

Implement increased documentation and reporting processes for traditional herbal medicinal products. Ensure staff receive training on the complexities involved in signal management for these products.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward
publicHealth Canada · Canada · Updated Jul 15, 2026

Order Providing for Reliance on Foreign Regulatory Authority Decisions for Certain Drugs (Ministerial Reliance Order)

Urgency: High

Manufacturers must demonstrate that any variances from the foreign authorized drugs do not adversely affect safety or effectiveness when filing for deeming under this new framework.

Country ComplianceSignal ManagementRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, QPPV
verifiedRegulatory action: Draft Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency · European Union · Updated Jul 10, 2026

PRAC 6-9 July 2026: Agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata News Human Pharmacovigilance Download medicine d

Urgency: High

MAHs must execute safety communication plans, update Risk Management Plans (RMPs), and revise product information including the Summary of Product Characteristics (SmPC) and Package Leaflet.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact3 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead, Labeling Lead
verifiedRegulatory action: Meeting Highlights
Read impact briefarrow_forward